Scotland rapped over cardiovascular technology access failures
This article was originally published in Clinica
Much has been achieved in Scotland to improve access to optimum cardiovascular (CV) care, but more needs to be done to ensure more appropriate use of key medical technologies and medicines, according to a review of Scotland’s Heart Disease Improvement Programme (HDIP).
You may also be interested in...
A patent-litigation settlement that Teva has reached with Ironwood and Allergan over Linzess will allow the Israeli firm to enter the US market with the linaclotide-based constipation treatment ahead of major rivals Mylan, Sandoz, Sun Pharma and Aurobindo.
Following Aspen’s admission last year that it was party to an illegal, anti-competitive agreement on fludrocortisone, Tiofarma has now also conceded to the UK’s Competition and Markets Authority that it took part in the deal.